Highlights
- Third quarter 2026 revenue was
$202.7 million , representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively. - On
October 19, 2026 , entered into a definitive agreement to sell thePrenatal Health business to Labcorp for$210 million in cash, plus the value of related inventory at closing. Upon close, the sale is expected to be accretive to revenue growth and profitability, while strengthening the balance sheet. - Raises mid-point of full-year 2026 revenue guidance to reflect third quarter 2026 results and current business trends for the remainder of 2026.
“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC). Average revenue per CCC test in the third quarter 2026 was higher than in the second quarter 2026 and reflects our team's ongoing work and early progress with payer engagement and revenue cycle management initiatives," said
Financial and Operational Highlights
- Third quarter 2026 test volume for
Cancer Care Continuum and Mental Health increased 3% year-over-year to 239,000 tests, whilePrenatal Health test volume decreased 11% to 138,000 tests, reflecting ongoing trends in the business, which the Company recently announced it plans to divest. - Third quarter of 2026 average revenue per test increased 1% year-over-year reflecting product mix and incremental progress with payer engagement and revenue cycle management initiatives.
- The following table summarizes year-over-year testing volume changes in the company's core product categories:
| Three months ended | Nine months ended | ||||||||||||
| (in thousands) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||
| Product volumes: | |||||||||||||
| Cancer Care Continuum | 98 | 94 | 4 | % | 289 | 269 | 7 | % | |||||
| Mental Health | 141 | 137 | 3 | % | 417 | 399 | 5 | % | |||||
| Cancer Care Continuum and Mental Health Volume* | 239 | 231 | 3 | % | 706 | 668 | 6 | % | |||||
| 138 | 155 | (11) | % | 435 | 487 | (11) | % | ||||||
| Total | 377 | 386 | (2) | % | 1,141 | 1,155 | (1) | % | |||||
- The following table summarizes year-over-year revenue changes in the company's core product categories:
| Three months ended | Nine months ended | ||||||||||||||||
| (in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||
| Product revenues: | |||||||||||||||||
| Cancer Care Continuum | $ | 123.9 | $ | 122.5 | 1 | % | $ | 358.2 | $ | 365.8 | (2) | % | |||||
| Mental Health | 39.5 | 38.7 | 2 | % | 114.6 | 107.5 | 7 | % | |||||||||
| Cancer Care Continuum and Mental Health Revenue* | 163.4 | 161.2 | 1 | % | 472.8 | 473.3 | — | % | |||||||||
| 39.3 | 44.5 | (12) | % | 121.0 | 141.4 | (14) | % | ||||||||||
| Total | $ | 202.7 | $ | 205.7 | (1) | % | $ | 593.8 | $ | 614.7 | (3) | % | |||||
| * | On |
Product Categories:
Cancer Care Continuum – MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris + AI, Precise Tumor, Precise MRD
Mental Health – GeneSight
- Third quarter 2026 gross margin was 67.9%, down 200 basis points from the third quarter 2025, reflecting lower overall test volumes and incremental investments in laboratory personnel.
- Operating expenses in the third quarter of 2026 were
$177.6 million compared to$167.1 million in the third quarter of 2025. Adjusted operating expenses in the third quarter of 2026 increased$9.9 million year-over-year to$149.9 million , reflecting the company's multi-year investment in key strategic areas. - Operating loss in the third quarter of 2026 was
$39.9 million .
Cash Flow and Liquidity
Third quarter 2026 cash flow used in operations was
As of the end of the third quarter of 2026, the company had cash and cash equivalents of
Business Performance and Highlights
Cancer Care Continuum
The Cancer Care Continuum business delivered revenue of
- Third quarter 2026 hereditary cancer testing revenue decreased 1% year-over-year due to decreases in reimbursement levels, partially offset by a 6% year-over-year increase in volume. Average revenue per hereditary cancer test in the third quarter 2026 improved 9% over the second quarter 2026, reflecting early progress with revenue cycle initiatives and other programs.
- In late
October 2026 , new MONSTAR-SCREEN-3 data was presented as part of theEuropean Society for Medical Oncology Congress 2026. We believe this data reinforces the importance of highly sensitive molecular residual disease (MRD) testing after curative-intent surgery in patients with resectable colorectal and pancreatic cancers, where earlier insight into recurrence risk may help inform monitoring and treatment decisions. - The company continues to engage the Molecular Diagnostics Program, administered by
Palmetto GBA , a Medicare Administrative Contractor for theCenters for Medicare & Medicaid Services , for a Local Coverage Determination to establish Medicare coverage of its Precise MRD test for breast cancer patients. - In
October 2026 ,Myriad Genetics announced a collaboration withSOPHia GENETICS to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. - In
October 2026 , Dr.Luis Diaz Jr . and team atMemorial Sloan Kettering Cancer Center published findings in theAmerican Association for Cancer Research's Cancer Discovery Journal that further support broad-based germline testing beyond conventional age-based criteria, reflecting the prevalence of hereditary risk even among late-onset cancer cases1.
Mental Health
GeneSight test revenue was
- Third quarter 2026 revenue increased 2% year-over-year reflecting 3% year-over-year GeneSight volume growth, partially offset by a 1% year-over-year decline in average revenue per test, which reflects general market dynamics.
- Prenatal testing revenue in the third quarter 2026 declined 12% year-over-year, as volume decreased 11% year-over-year.
- On
October 19, 2026 , the company entered into a definitive agreement to sell itsPrenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests to Labcorp for$210 million in cash, plus the value of the inventory of thePrenatal Health business at closing. The transaction is subject to customary closing conditions, including regulatory approvals and is expected to close by early 2027.
Financial Guidance
Below is a table summarizing
| (in millions, except percentages) | 2026 Guidance | FY 2026 Comments | ||
| Revenue | Raised the mid-point of full-year 2026 revenue range, reflecting Q3 results and current business trends. | |||
| Cancer Care Continuum and Mental Health Revenue | With the announced sale of | |||
| Prenatal Health Revenue | ||||
| Adjusted Gross Margin %** | 66% - 67% | Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends. | ||
| * | Assumes currency rates as of | |||
| ** | Adjusted Gross Margin is defined as Gross Margin plus non-cash cost of sales, such as amortization of intangible assets and share-based compensation expense, and non-recurring one-time expenses such as expenses from strategic realignment and other adjustments. | |||
These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.
Conference Call and Webcast
A conference call will be held today,
About
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, MyChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, myGeneHistory, Health.Illuminated., RiskScore, Prolaris, Prolaris + AI, and GeneSight are registered trademarks or trademarks of
© 2026
AND SUBSIDIARIES Condensed Consolidated Statements of Operations (unaudited) (in millions, except per share amounts) | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | $ | 202.7 | $ | 205.7 | $ | 593.8 | $ | 614.7 | |||||||
| Cost of revenue | 65.0 | 61.9 | 191.5 | 184.9 | |||||||||||
| Gross profit | 137.7 | 143.8 | 402.3 | 429.8 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development expense | 26.5 | 28.2 | 78.6 | 81.3 | |||||||||||
| Sales and marketing expense | 83.9 | 71.0 | 240.6 | 212.1 | |||||||||||
| General and administrative expense | 67.2 | 67.9 | 187.2 | 201.2 | |||||||||||
| — | — | 5.4 | 316.7 | ||||||||||||
| Total operating expenses | 177.6 | 167.1 | 511.8 | 811.3 | |||||||||||
| Operating loss | (39.9 | ) | (23.3 | ) | (109.5 | ) | (381.5 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 0.6 | 0.5 | 1.7 | 1.0 | |||||||||||
| Interest expense | (4.1 | ) | (3.8 | ) | (12.3 | ) | (6.1 | ) | |||||||
| Other | (0.2 | ) | 0.4 | (0.2 | ) | 0.4 | |||||||||
| Total other expense | (3.7 | ) | (2.9 | ) | (10.8 | ) | (4.7 | ) | |||||||
| Loss before income tax | (43.6 | ) | (26.2 | ) | (120.3 | ) | (386.2 | ) | |||||||
| Income tax expense (benefit) | 0.3 | 1.2 | 0.9 | (28.2 | ) | ||||||||||
| Net loss | $ | (43.9 | ) | $ | (27.4 | ) | $ | (121.2 | ) | $ | (358.0 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic and diluted | $ | (0.46 | ) | $ | (0.29 | ) | $ | (1.28 | ) | $ | (3.88 | ) | |||
| Weighted average shares outstanding: | |||||||||||||||
| Basic and diluted | 95.7 | 93.1 | 94.7 | 92.3 | |||||||||||
AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) (in millions, except per share amounts) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 107.1 | $ | 149.6 | |||
| Trade accounts receivable | 105.5 | 115.3 | |||||
| Inventory | 28.6 | 30.6 | |||||
| Prepaid taxes | 1.5 | 12.0 | |||||
| Prepaid expenses and other current assets | 29.2 | 25.1 | |||||
| Total current assets | 271.9 | 332.6 | |||||
| Operating lease right-of-use assets | 48.9 | 49.4 | |||||
| Property, plant and equipment, net | 104.7 | 114.0 | |||||
| Intangible assets, net | 131.8 | 153.4 | |||||
| 47.1 | 51.6 | ||||||
| Other assets | 4.8 | 5.6 | |||||
| Total assets | $ | 609.2 | $ | 706.6 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 27.6 | $ | 30.0 | |||
| Accrued liabilities | 102.2 | 96.9 | |||||
| Current maturities of operating lease liabilities | 7.8 | 6.9 | |||||
| Total current liabilities | 137.6 | 133.8 | |||||
| Long-term debt | 121.1 | 119.9 | |||||
| Noncurrent operating lease liabilities | 80.5 | 83.0 | |||||
| Other long-term liabilities | 1.0 | 1.9 | |||||
| Total liabilities | 340.2 | 338.6 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock, 95.7 and 93.5 shares outstanding at | 1.0 | 0.9 | |||||
| Additional paid-in capital | 1,511.2 | 1,489.0 | |||||
| Accumulated other comprehensive income | 0.7 | 0.8 | |||||
| Accumulated deficit | (1,243.9 | ) | (1,122.7 | ) | |||
| Total stockholders' equity | 269.0 | 368.0 | |||||
| Total liabilities and stockholders’ equity | $ | 609.2 | $ | 706.6 | |||
AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (unaudited) (in millions) | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net cash used in operating activities | $ | (6.5 | ) | $ | 21.1 | $ | (30.5 | ) | $ | (8.8 | ) | ||||
| Net cash used in investing activities | (2.1 | ) | (6.2 | ) | (11.8 | ) | (21.4 | ) | |||||||
| Net cash provided by (used in) financing activities | (0.3 | ) | 56.2 | (1.1 | ) | 72.4 | |||||||||
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | (0.1 | ) | — | (0.1 | ) | 0.7 | |||||||||
| Net decrease in cash, cash equivalents, and restricted cash | (9.0 | ) | 71.1 | (43.5 | ) | 42.9 | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of the period | 116.8 | 83.7 | 151.3 | 111.9 | |||||||||||
| Cash, cash equivalents, and restricted cash at end of the period | $ | 107.8 | $ | 154.8 | $ | 107.8 | $ | 154.8 | |||||||
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to (i) the company's full-year 2026 financial guidance, (ii) the sale of the company's
These risks include, but are not limited to: the risk that sales and profit margins of the company’s existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to recent changes in the company's senior management team and the successful implementation of the company's strategic plan; risks related to the sale of certain assets of the company's
| Investor Contact |
| (801) 584-3532 |
| matt.scalo@myriad.com |
| Media Contact |
| Kate Schraml |
| (224) 875-4493 |
| PR@myriad.com |
Statement Regarding Use of Non-GAAP Financial Measures
In this press release, the company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, if available, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
The company does not forecast GAAP gross margin because it cannot predict certain elements that are included in reported GAAP results. Please see above under “Financial Guidance” for a full explanation.
Reconciliation of GAAP to Non-GAAP Financial Measures
for the Three and Nine Months Ended
(unaudited data in millions, except per share amounts)
| Three months ended | Nine months ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Adjusted Gross Margin | |||||||||||||||||
| Gross Profit | $ | 137.7 | $ | 143.8 | $ | 402.3 | $ | 429.8 | |||||||||
| Acquisition - amortization of intangible assets(1) | — | — | 0.1 | 0.6 | |||||||||||||
| Equity compensation(2) | 0.2 | 0.3 | 0.9 | 0.9 | |||||||||||||
| Strategic realignment(3) | 0.4 | — | 0.4 | — | |||||||||||||
| Other adjustments(4) | — | — | — | 0.3 | |||||||||||||
| Adjusted Gross Profit | $ | 138.3 | $ | 144.1 | $ | 403.7 | $ | 431.6 | |||||||||
| Adjusted Gross Margin | 68.2 | % | 70.1 | % | 68.0 | % | 70.2 | % | |||||||||
| (1) | Represents recurring amortization charges resulting from the acquisition of intangible assets. | ||||||||||||||||
| (2) | Consists of the non-cash equity-based compensation provided to | ||||||||||||||||
| (3) | Costs related to strategic realignment of the company including severance and consulting fees. | ||||||||||||||||
| (4) | Other one-time non-recurring adjustments. | ||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Adjusted Operating Expenses | |||||||||||||||||
| Operating Expenses | $ | 177.6 | $ | 167.1 | $ | 511.8 | $ | 811.3 | |||||||||
| Acquisition - amortization of intangible assets(1) | (6.5 | ) | (6.5 | ) | (19.3 | ) | (23.4 | ) | |||||||||
| — | — | (5.4 | ) | (316.7 | ) | ||||||||||||
| Equity compensation(3) | (9.0 | ) | (11.9 | ) | (22.0 | ) | (31.5 | ) | |||||||||
| Real estate optimization(4) | — | — | — | (5.2 | ) | ||||||||||||
| Strategic realignment(5) | (12.2 | ) | (8.3 | ) | (16.2 | ) | (10.1 | ) | |||||||||
| Other adjustments(6) | — | (0.4 | ) | — | — | ||||||||||||
| Adjusted Operating Expenses | $ | 149.9 | $ | 140.0 | $ | 448.9 | $ | 424.4 | |||||||||
| (1) | Represents recurring amortization charges resulting from the acquisition of intangible assets. | ||||||||||||||||
| (2) | Expense related to goodwill and long-lived asset impairment. For the nine months ended | ||||||||||||||||
| (3) | Consists of the non-cash equity-based compensation provided to | ||||||||||||||||
| (4) | Costs related to real estate initiatives. For the nine months ended | ||||||||||||||||
| (5) | Costs related to strategic realignment of the company including severance and consulting fees. | ||||||||||||||||
| (6) | Other one-time non-recurring adjustments. | ||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Adjusted Net Income (Loss)(1) | |||||||||||||||||
| Net Loss | $ | (43.9 | ) | $ | (27.4 | ) | $ | (121.2 | ) | $ | (358.0 | ) | |||||
| Acquisition - amortization of intangible assets(2) | 6.5 | 6.5 | 19.4 | 24.0 | |||||||||||||
| — | — | 5.4 | 316.7 | ||||||||||||||
| Equity compensation(4) | 9.2 | 12.2 | 22.9 | 32.4 | |||||||||||||
| Real estate optimization(5) | — | — | — | 5.2 | |||||||||||||
| Strategic realignment(6) | 12.6 | 8.3 | 16.6 | 10.1 | |||||||||||||
| Other adjustments(7) | — | 0.4 | — | 0.4 | |||||||||||||
| Uncertain tax benefit(8) | — | — | — | (29.0 | ) | ||||||||||||
| Tax adjustments(9) | 4.9 | 0.2 | 14.6 | 0.1 | |||||||||||||
| Adjusted Net Income (Loss) | $ | (10.7 | ) | $ | 0.2 | $ | (42.3 | ) | $ | 1.9 | |||||||
| Weighted average shares outstanding: | |||||||||||||||||
| Diluted | 95.7 | 93.8 | 94.7 | 93.2 | |||||||||||||
| Adjusted Income (Loss) Per Share | |||||||||||||||||
| Diluted | $ | (0.11 | ) | $ | — | $ | (0.45 | ) | $ | 0.02 | |||||||
| (1) | To determine Adjusted Income (Loss) Per Share. | ||||||||||||||||
| (2) | Represents recurring amortization charges resulting from the acquisition of intangible assets. | ||||||||||||||||
| (3) | Expense related to goodwill and long-lived asset impairment. For the nine months ended | ||||||||||||||||
| (4) | Consists of the non-cash equity-based compensation provided to | ||||||||||||||||
| (5) | Costs related to real estate initiatives. For the nine months ended | ||||||||||||||||
| (6) | Costs related to strategic realignment of the company including severance and consulting fees. | ||||||||||||||||
| (7) | Other one-time non-recurring adjustments. | ||||||||||||||||
| (8) | Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended | ||||||||||||||||
| (9) | Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in | ||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Adjusted EBITDA | |||||||||||||||||
| Net Loss | $ | (43.9 | ) | $ | (27.4 | ) | $ | (121.2 | ) | $ | (358.0 | ) | |||||
| Acquisition - amortization of intangible assets(1) | 6.5 | 6.5 | 19.4 | 24.0 | |||||||||||||
| Depreciation expense(2) | 4.9 | 4.8 | 14.4 | 14.8 | |||||||||||||
| — | — | 5.4 | 316.7 | ||||||||||||||
| Equity compensation(4) | 9.2 | 12.2 | 22.9 | 32.4 | |||||||||||||
| Real estate optimization(5) | — | — | — | 5.2 | |||||||||||||
| Strategic realignment(6) | 12.6 | 8.3 | 16.6 | 10.1 | |||||||||||||
| Interest expense, net of interest income(7) | 3.5 | 3.3 | 10.6 | 5.1 | |||||||||||||
| Other adjustments(8) | 1.6 | 1.4 | 4.3 | 2.5 | |||||||||||||
| Uncertain tax benefits(9) | — | — | — | (29.0 | ) | ||||||||||||
| Income tax expense(10) | 0.3 | 1.2 | 0.9 | 0.8 | |||||||||||||
| Adjusted EBITDA | $ | (5.3 | ) | $ | 10.3 | $ | (26.7 | ) | $ | 24.6 | |||||||
| (1) | Represents recurring amortization charges resulting from the acquisition of intangible assets. | ||||||||||||||||
| (2) | Consists of depreciation expense recognized during the period. | ||||||||||||||||
| (3) | Expense related to goodwill and long-lived asset impairment. For the nine months ended | ||||||||||||||||
| (4) | Consists of the non-cash equity-based compensation provided to | ||||||||||||||||
| (5) | Costs related to real estate initiatives. For the nine months ended | ||||||||||||||||
| (6) | Costs related to strategic realignment of the company including severance and consulting fees. | ||||||||||||||||
| (7) | Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations. | ||||||||||||||||
| (8) | Other one-time non-recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in the Adjusted Net Income (Loss) table above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement of Operations. | ||||||||||||||||
| (9) | Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended | ||||||||||||||||
| (10) | Derived from Income tax expense (benefit) from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described in Note 9 above. | ||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Adjusted Operating and Free Cash Flow | |||||||||||||||||
| Net Cash Provided by (Used in) Operating Activities | $ | (6.5 | ) | $ | 21.1 | $ | (30.5 | ) | $ | (8.8 | ) | ||||||
| Real estate optimization(1) | — | 1.2 | — | 8.7 | |||||||||||||
| Strategic realignment(2) | 10.2 | 2.3 | 13.1 | 4.1 | |||||||||||||
| Other adjustments(3) | — | 0.2 | — | 0.2 | |||||||||||||
| Adjusted Operating Cash Flow | $ | 3.7 | $ | 24.8 | $ | (17.4 | ) | $ | 4.2 | ||||||||
| Capital expenditures(4) | (1.8 | ) | (2.8 | ) | (9.3 | ) | (10.9 | ) | |||||||||
| Capitalization of internal-use software costs(4) | (0.3 | ) | (3.4 | ) | (2.5 | ) | (10.5 | ) | |||||||||
| Adjusted Free Cash Flow | $ | 1.6 | $ | 18.6 | $ | (29.2 | ) | $ | (17.2 | ) | |||||||
| (1) | The cash flow effect of real estate optimizations, excluding non-cash items such as accelerated depreciation. | ||||||||||||||||
| (2) | Strategic realignment includes the cash paid for severance and consulting fees. | ||||||||||||||||
| (3) | The cash flow effect of other one-time non-recurring expenses. | ||||||||||||||||
| (4) | Derived from the Condensed Consolidated Statements of Cash Flows. | ||||||||||||||||
1 Cancer Discov. 2026 Oct 8:OF1-OF9. doi: 10.1158/2159-8290.CD-26-0971.
Source: